No Data
No Data
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Promising Developments in Gain Therapeutics' Parkinson's Treatment Justify Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Gain Therapeutics (GANX)
Gain Therapeutics Unveils New Parkinson's Treatment Data
Gain Therapeutics Presents Additional Data on Study of GT-02287
Gain Therapeutics Targets Phase 2 as GT-02287 Phase 1b Biomarker Readout Set for Mid-2025